CN1524002A - 治疗或预防产胰岛素细胞的移植排斥反应 - Google Patents

治疗或预防产胰岛素细胞的移植排斥反应 Download PDF

Info

Publication number
CN1524002A
CN1524002A CNA028098498A CN02809849A CN1524002A CN 1524002 A CN1524002 A CN 1524002A CN A028098498 A CNA028098498 A CN A028098498A CN 02809849 A CN02809849 A CN 02809849A CN 1524002 A CN1524002 A CN 1524002A
Authority
CN
China
Prior art keywords
insulin
antibody
combined according
medication combined
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028098498A
Other languages
English (en)
Chinese (zh)
Inventor
P
P·莱克
C·米隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1524002A publication Critical patent/CN1524002A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CNA028098498A 2001-06-08 2002-06-07 治疗或预防产胰岛素细胞的移植排斥反应 Pending CN1524002A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
US60/297,069 2001-06-08

Publications (1)

Publication Number Publication Date
CN1524002A true CN1524002A (zh) 2004-08-25

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028098498A Pending CN1524002A (zh) 2001-06-08 2002-06-07 治疗或预防产胰岛素细胞的移植排斥反应

Country Status (18)

Country Link
US (5) US20030003099A1 (enExample)
EP (1) EP1429845B1 (enExample)
JP (1) JP4476623B2 (enExample)
CN (1) CN1524002A (enExample)
AT (1) ATE424893T1 (enExample)
AU (1) AU2002320828B2 (enExample)
BR (1) BR0209319A (enExample)
CA (1) CA2445605A1 (enExample)
DE (1) DE60231522D1 (enExample)
ES (1) ES2322442T3 (enExample)
IL (1) IL158384A0 (enExample)
NO (1) NO20035434D0 (enExample)
NZ (1) NZ529044A (enExample)
PL (1) PL364359A1 (enExample)
PT (1) PT1429845E (enExample)
RU (1) RU2003136730A (enExample)
WO (1) WO2002100148A2 (enExample)
ZA (1) ZA200307893B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267993T3 (es) * 2001-02-22 2007-03-16 Novartis Ag Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto.
CA2566716C (en) * 2004-05-14 2014-12-23 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
MX2007009534A (es) * 2005-02-08 2007-09-21 Novartis Ag Induccion de anticuerpo antilinfocito mediante la combinacion de un agonista/ modulador del receptor s1p y de farmacos inmunosupresivos.
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
ES2348701T3 (es) * 2005-05-11 2010-12-10 Loma Linda University Composiciones y mã‰todos para prevenir y tratar trastornos inflamatorios de mediaciã“n inmune.
AU2006325931B8 (en) 2005-12-15 2012-09-20 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
EP2489729B1 (en) * 2006-09-28 2015-02-25 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering RNA
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
CA2716058C (en) * 2008-03-12 2016-07-05 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
PT2356090T (pt) * 2008-11-11 2017-10-16 Novartis Ag Formas cristalinas de fingolimod, hcl
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
BRPI1015133A2 (pt) * 2009-06-30 2016-04-19 Lifescan Scotland Ltd sistemas para o gerenciamento de diabetes e métodos
EP2448469B1 (en) * 2009-06-30 2021-07-21 Lifescan, Inc. Analyte testing methods and device for calculating basal insulin therapy
JP5657678B2 (ja) * 2009-09-29 2015-01-21 ライフスキャン・スコットランド・リミテッドＬｉｆｅＳｃａｎ Ｓｃｏｔｌａｎｄ， Ｌｔｄ． 糖尿病管理のための分析物試験方法及びデバイス
CN102770868B (zh) * 2010-02-25 2017-02-22 生命扫描苏格兰有限公司 具有高低血糖趋势通知的分析物测试方法和系统
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
EP3760226A1 (en) 2011-09-23 2021-01-06 Loma Linda University Bacterial strains expressing methylase genes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
WO1995023512A1 (en) * 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
ES2267993T3 (es) * 2001-02-22 2007-03-16 Novartis Ag Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600472A (zh) * 2004-11-29 2012-07-25 诺瓦提斯公司 S1p受体激动剂的剂量方案
CN101068536B (zh) * 2004-11-29 2012-12-05 诺瓦提斯公司 S1p受体激动剂的剂量方案
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Also Published As

Publication number Publication date
CA2445605A1 (en) 2002-12-19
WO2002100148A3 (en) 2004-04-22
US20080199465A1 (en) 2008-08-21
US20110236382A1 (en) 2011-09-29
WO2002100148A2 (en) 2002-12-19
BR0209319A (pt) 2004-07-20
JP4476623B2 (ja) 2010-06-09
RU2003136730A (ru) 2005-05-20
ZA200307893B (en) 2004-09-06
EP1429845A2 (en) 2004-06-23
ATE424893T1 (de) 2009-03-15
ES2322442T3 (es) 2009-06-22
NO20035434D0 (no) 2003-12-05
AU2002320828B2 (en) 2006-02-02
PT1429845E (pt) 2009-06-15
US20030003099A1 (en) 2003-01-02
IL158384A0 (en) 2004-05-12
JP2004534788A (ja) 2004-11-18
US20060153842A1 (en) 2006-07-13
PL364359A1 (en) 2004-12-13
US20140093502A1 (en) 2014-04-03
EP1429845B1 (en) 2009-03-11
DE60231522D1 (de) 2009-04-23
NZ529044A (en) 2008-03-28

Similar Documents

Publication Publication Date Title
CN1524002A (zh) 治疗或预防产胰岛素细胞的移植排斥反应
AU2002320828A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
Brinkmann et al. FTY720: altered lymphocyte traffic results in allograft protection
KR101650264B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
Frei et al. Local delivery of fingolimod from three‐dimensional scaffolds impacts islet graft efficacy and microenvironment in a murine diabetic model
KR20180041229A (ko) 줄기 세포 이식을 위한 방법
CN100427097C (zh) 霉酚酸、其盐或前体药物的胃肠外制剂
Bertuzzi et al. Brittle type 1 diabetes mellitus
RU2424795C2 (ru) Лечение аутоиммунных заболеваний
EP1368015B1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
KR20120083440A (ko) 이자섬 이식에서 보조제로서 ｃｘｃｒ1/2의 억제제
CN1930123A (zh) 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
US20110281944A1 (en) Method of a rhein compound for inhibiting pancreatic islet beta-cell dysfunction and preventing or treating a pancreatic islet beta-cell dysfunction related disorder
CN1901906A (zh) 治疗套细胞淋巴瘤的cci－779
WO2022155152A1 (en) Htr1f antagonists for improvement of beta cell survival and function
CN103930101A (zh) 用fty720治疗2型糖尿病
EP1632229A1 (en) Medicaments for the treatment of urinary tract disorders comprising anticholinergic agents
JP5727167B2 (ja) Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
CN119907677A (zh) 在治疗黄斑水肿或视网膜静脉阻塞中使用的单体膜联蛋白a5
CA3157631A1 (en) Use of compound in preventing or treating graft versus host disease
CN1703236A (zh) Il－2 受体抗体用于预防与两性霉素b抗真菌疗法有关的毒性的应用
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
Eskens Role for the endothelial glycocalyx in regulation of insulin sensitivity in muscle

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20040825